文献速递慢性肾脏病肾血管病与高血压

α受体阻滞剂在CKD患者中的肾脏、心脏及安全性结局:基于人群的队列研究

Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2020-09-11

该研究基于加拿大安大略省66岁及以上高血压患者的人群回顾性队列,比较新使用α受体阻滞剂与非α受体阻滞剂降压药者的结局。结果显示α受体阻滞剂与eGFR下降≥30%及肾脏替代治疗风险升高相关,但心脏事件风险降低,eGFR<60时死亡风险降低。

要点

  • α受体阻滞剂与eGFR下降≥30%风险升高相关(HR 1.14)。
  • α受体阻滞剂与肾脏替代治疗风险升高相关(HR 1.28)。
  • α受体阻滞剂与心脏事件风险降低相关(HR 0.92),eGFR<60时死亡风险降低。

核心结论

  • 在CKD患者中,α受体阻滞剂使用与肾脏疾病进展风险升高相关,但与非α受体阻滞剂降压药相比心脏事件和死亡风险更低。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入2007至2015年加拿大安大略省66岁及以上、无α受体阻滞剂既往处方的高血压患者。
  • 共381,120名符合条件个体,其中16,088名使用α受体阻滞剂者通过高维倾向评分1:1匹配至非α受体阻滞剂使用者。

主要发现

  • α受体阻滞剂使用与eGFR下降≥30%风险升高相关(HR 1.14;95%CI 1.08-1.21)。
  • α受体阻滞剂使用与肾脏替代治疗风险升高相关(HR 1.28;95%CI 1.13-1.44)。
  • eGFR水平未修饰上述肾脏结局关联(交互P值分别为0.3和0.3)。
  • α受体阻滞剂使用与心脏事件风险降低相关(HR 0.92;95%CI 0.89-0.95),且在各eGFR类别中一致(交互P=0.1)。
  • α受体阻滞剂使用与死亡风险降低相关,但仅限于eGFR<60mL/min/1.73m2者(交互P<0.001):eGFR 30-59者HR 0.85(95%CI 0.78-0.93),eGFR<30者HR 0.71(95%CI 0.64-0.80)。

临床怎么用

  • 在CKD高血压患者中使用α受体阻滞剂时,需权衡肾脏进展风险与心脏事件及死亡风险降低的潜在获益。

局限性

  • 观察性设计,缺乏血压测量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVES: Alpha-blockers (ABs) are commonly prescribed for control of resistant or refractory hypertension in patients with and without chronic kidney disease (CKD). The association between AB use and kidney, cardiac, mortality, and safety-related outcomes in CKD remains unknown. STUDY DESIGN: Population-based retrospective cohort study. SETTINGS & PARTICIPANTS: Ontario (Canada) residents 66 years and older treated for hypertension in 2007 to 2015 without a prior prescription for an AB. EXPOSURES: New use of an AB versus new use of a non-AB blood pressure (BP)-lowering medication. OUTCOMES: 30% or greater estimated glomerular filtration rate (eGFR) decline; dialysis initiation or kidney transplantation (kidney replacement therapy); composite of acute myocardial infarction, coronary revascularization, congestive heart failure, or atrial fibrillation; safety (hypotension, syncope, falls, and fractures) events; and mortality. ANALYTICAL APPROACH: New users of ABs (doxazosin, terazosin, and prazosin) were matched to new users of non-ABs by a high dimensional propensity score. Cox proportional hazards and Fine and Gray models were used to examine the association of AB use with kidney, cardiac, mortality, and safety outcomes. Interactions by eGFR categories (≥90, 60-89, 30-59, and<30mL/min/1.73m2) were explored. RESULTS: Among 381,120 eligible individuals, 16,088 were dispensed ABs and matched 1:1 to non-AB users. AB use was associated with higher risk for≥30% eGFR decline (HR, 1.14; 95% CI, 1.08-1.21) and need for kidney replacement therapy (HR, 1.28; 95% CI, 1.13-1.44). eGFR level did not modify these associations, P interaction=0.3and 0.3, respectively. Conversely, AB use was associated with lower risk for cardiac events, which was also consistent across eGFR categories (HR, 0.92; 95% CI, 0.89-0.95; P interaction=0.1). AB use was also associated with lower mortality risk, but only among those with eGFR<60mL/min/1.73m2 (P interaction<0.001): HRs were 0.85 (95% CI, 0.78-0.93) and 0.71 (95% CI, 0.64-0.80) for eGFR of 30 to 59 and<30mL/min/1.73m2, respectively. LIMITATIONS: Observational design, BP measurement data unavailable. CONCLUSIONS: AB use in CKD is associated with higher risk for kidney disease progression but lower risk for cardiac events and mortality compared with alternative BP-lowering medications.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Hundemer GL, Knoll GA, Petrcich W, et al. Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study. Am J Kidney Dis. 2020. PMID: 32920153. doi:10.1053/j.ajkd.2020.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。